Allogene Therapeutics Closes $200.4 Million Public Offering, Securing Capital
Summary
Allogene Therapeutics announced the closing of its public offering of common stock, raising $200.4 million. This follows the company's recent positive Phase 2 ALPHA3 trial results on April 13th, which was immediately followed by the proposal and subsequent pricing of an underwritten public offering, initially targeting $175 million. The final $200.4 million amount indicates an upsize or exercise of the over-allotment option, suggesting strong demand. While this capital raise significantly bolsters Allogene's financial position and extends its cash runway, it also confirms a material dilutive impact for existing shareholders. Traders will now focus on the company's strategic use of these funds.
At the time of this announcement, ALLO was trading at $2.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $577.8M. The 52-week trading range was $0.86 to $4.46. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.